business
GSK Profit Beats Estimates on HIV, Cancer Medicines
GSK Plc’s profit was higher than analysts expected in the first quarter, helped by the drugmaker’s specialty medicines for HIV, cancer and immune diseases.
Read full story on Bloomberg Markets → More top storiesAlso covered by
Aggregated and edited by the Scoop newsroom. We surface news from Bloomberg Markets alongside other reporting so you can compare coverage in one place.
Editorial policy · Corrections · About Scoop